Akebia Therapeutics (AKBA) vs Foghorn Therapeutics (FHTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Foghorn Therapeutics (FHTX) has outperformed Akebia Therapeutics (AKBA) over the past year, losing 62.8% versus a loss of 75.1%. Over five years, AKBA leads with a -85.6% price change compared with -87.4% for FHTX. Akebia Therapeutics is the larger company by market cap ($107.0 million vs $103.1 million), about 1.0 times the size.
Akebia Therapeutics converts more of its revenue into profit, with a net margin of -2.3% versus -240.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKBA | FHTX |
|---|---|---|
| Share price | $0.3855 | $1.72 |
| Market cap | $107.04M | $103.14M |
| 1-day change | -8.71% | -3.37% |
| YTD return | -76.06% | -68.15% |
| 1-year return | -75.13% | -62.77% |
| 5-year return | -85.56% | -87.36% |
| P/E ratio (TTM) | — | 19.11 |
| EPS (TTM) | $-0.17 | $0.09 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $236.20M | $30.91M |
| Revenue growth (YoY) | +47.46% | +36.75% |
| Net income (latest FY) | $-5.34M | $-74.28M |
| Gross margin | 83.29% | — |
| Operating margin | 9.95% | -279.49% |
| Net margin | -2.26% | -240.33% |
| 52-week high | $1.73 | $7.61 |
| 52-week low | $0.361 | $1.66 |
| Distance from 52-week high | -77.72% | -77.40% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +678.21% | +142.44% |
| Average volume | 8.05M | 843.73K |
| Shares outstanding | 277.66M | 59.96M |
| Employees | 194 | 106 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FHTX has outperformed AKBA by 12.4 percentage points over the past year.
- Akebia Therapeutics is more profitable, keeping -2.3 cents of every revenue dollar as net income versus -240.3 cents for Foghorn Therapeutics.
- Akebia Therapeutics grew revenue faster in its latest fiscal year (+47.46% vs +36.75%).
About Akebia Therapeutics
AKBA stock →Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD.
Health Care · Biotechnology: Pharmaceutical Preparations · 194 employees
About Foghorn Therapeutics
FHTX stock →Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
AKBA vs FHTX FAQ
Which is bigger, Akebia Therapeutics or Foghorn Therapeutics?
Akebia Therapeutics (AKBA) is larger, with a market capitalization of $107.04M compared with $103.14M for Foghorn Therapeutics (FHTX).
Which stock has performed better over the past year, AKBA or FHTX?
FHTX returned -62.77% over the past 12 months, compared with -75.13% for AKBA (price return, excluding dividends). Past performance does not predict future results.
Are Akebia Therapeutics and Foghorn Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.